2025-10-01T13:45:42-05:00 2024-12-31 930623286 ALDRICH CPAS AND ADVISORS LLP 1903 WRIGHT PLACE 180 CARLSBAD CA 92008 990 2024-01-01 460552414 CUREBOUND CURE 6193145878 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 ANNE MARBARGER CHIEF EXECUTIVE OFFICER 6193145878 2025-09-30 1 1 DEBRA D SMITH CPA P00646873 7604318440 2025-09-30 2024 2025-03-06 01:10:19Z ANNE MARBARGER 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 6405744 0 X WWW.CUREBOUND.ORG X 2012 CA MOBILIZE SAN DIEGO TO ACCELERATE CURES FOR CANCER IN OUR LIFETIME. 19 17 14 439 0 0 7931168 5672165 0 0 246733 522299 2217627 -705563 10395528 5488901 8400965 7083484 0 0 759178 1962733 0 0 796265 3340199 1698226 12500342 10744443 -2104814 -5255542 24388123 16440883 6208916 3522339 18179207 12918544 X THE ORGANIZATION'S MISSION IS TO PROVIDE FUNDING FOR THE BEST CANCER RESEARCH IDEAS IN SAN DIEGO. ALL PROCEEDS FROM CUREBOUND STAY IN SAN DIEGO TO FUND INNOVATIVE AND COLLABORATIVE CANCER RESEARCH. 0 0 8460867 7083484 CUREBOUND LEADS WITH A TRULY UNIQUE INVESTMENT MODEL FOCUSED ON CROSS INSTITUTIONAL COLLABORATION. THIS APPROACH BRINGS TOGETHER IDEAS, TECHNOLOGIES, AND RESEARCH APPROACHES THAT SIMPLY CANNOT OCCUR WITHIN ONE INSTITUTION AND ULTIMATELY ACCELERATES DISCOVERIES TO CLINICAL APPLICATION TO SAVE LIVES. THE RESEARCH TEAM FUNDED REPRESENT THE THREE NCI CANCER CENTERS IN SAN DIEGO WITH MOORES CANCER CENTER AT UC SAN DIEGO HEALTH, THE SALK INSTITUTE, AND SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE. ALSO, RADY CHILDREN'S HOSPITAL, SCRIPPS RESEARCH, AND THE LA JOLLA INSTITUTE OF IMMUNOLOGY. WE ESTABLISHED THE CANCER RESEARCH PROGRAM TO FUND THE MOST PROMISING, INNOVATIVE ONCOLOGY RESEARCH ACROSS ALL CANCER TYPES IN ALIGNMENT WITH FIVE SCIENTIFIC INVESTMENT PILLARS PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITES, AND PEDIATRIC CANCERS. THIS YEAR ALONE, OVER TWO MILLION PEOPLE WILL BE DIAGNOSED WITH CANCER, AND IT IS THE NUMBER TWO CAUSE OF DEATH IN THE UNITED STATES. OUR MISSION IS TO MOBILIZE SAN DIEGO TO ACCELERATE CURES FOR CANCER IN OUR LIFETIME. AND THE VISION OF CUREBOUND IS A WORLD WITHOUT CANCER. CUREBOUND IS HEADQUARTERED IN SAN DIEGO AMIDST A UNIQUE COMBINATION OF THREE NCI CANCER CENTERS, CLINICAL CARE HOSPITALS, BIOTECH COMPANIES, VENTURE CAPITAL INVESTORS, PHILANTHROPIC NETWORKS, AND MOST IMPORTANTLY- A REGIONAL CULTURE THAT EMBRACES THE SPIRIT OF COLLABORATION. THIS ECOSYSTEM POSITIONS SAN DIEGO AND CUREBOUND AT THE FOREFRONT OF DISCOVERY BRINGING GENOMIC MEDICINE, NEW TECHNOLOGIES AND CLINICAL TRIALS TO MARKET AND PRESENTS AN UNPRECEDENTED OPPORTUNITY FOR RESEARCH COLLABORATION. WE BELIEVE THAT THE NEXT DECADE WILL BE CRITICAL TO THE DEVELOPMENT OF SOPHISTICATED, PERSONALIZED APPROACHES IN THE WAY WE PREVENT, TREAT, AND ULTIMATELY FIND CURES FOR CANCER. 8460867 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 24 0 14 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 19 17 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X CUREBOUND 6193145878 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 FE WHITWORTH DIRECTOR 1.00 X 0 0 0 CHERYL AM ANDERSON DIRECTOR 1.00 X 0 0 0 LARRY BLOCH DIRECTOR 1.00 X 0 0 0 MARK CAFFERTY DIRECTOR 1.00 X 0 0 0 AARON DAVIS DIRECTOR 1.00 X 0 0 0 RICH HEYMAN DIRECTOR 1.00 X 0 0 0 JOHN HOOD DIRECTOR 1.00 X 0 0 0 CATRIONA JAMIESON DIRECTOR 1.00 X 0 0 0 DONALD B KEARNS DIRECTOR 1.00 X 0 0 0 JULIE TAFEL KLAUS DIRECTOR 1.00 X 0 0 0 MAGDA MARQUET DIRECTOR 1.00 X 0 0 0 DAN RYAN DIRECTOR 1.00 X 0 0 0 ROB SINGH DIRECTOR 1.00 X 0 0 0 HAEYOUNG TANG DIRECTOR 1.00 X 0 0 0 CHRIS TRESSE DIRECTOR 1.00 X 0 0 0 COURT TURNER DIRECTOR 1.00 X 0 0 0 BILL KOMAN CHAIRPERSON 1.00 X 0 0 0 RICK VALENCIA VICE-CHAIR 1.00 X 0 0 0 ROBIN TOFT SECRETARY 1.00 X 0 0 0 DON ANKENY TREASURER 1.00 X 0 0 0 ANNE MARBARGER CHIEF EXECUTIVE OFFICER 40.00 X 385000 0 25113 KAREN HOOPER CHIEF OPERATING OFFICER 40.00 X 230000 0 22935 DANIELLE DAWSON PHILANTHROPY OFFICER 40.00 X 221250 0 9889 HEATHER DEAN-PRESNALL SR. DIRECTOR, STEWARDSHIP + REVENUE STRATEGY 40.00 X 125000 0 18409 MEGAN AMBROSE CHIEF OF STAFF 40.00 X 113937 0 10697 1075187 0 87043 5 0 1 0 KATE SINCLAIR C/O 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 MARKETING/BRAND CONSULTING 213000 EZRA COHEN C/O 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 RESEARCH CONSULTANT 120000 CLARE MCGOWEN C/O 9605 SCRANTON ROAD SUITE 120 SAN DIEGO CA 92121 RESEARCH CONSULTANT 120000 3 3413332 2258833 5672165 522299 522299 211280 3413332 916843 -705563 -705563 5488901 0 0 -183264 7083484 7083484 894209 423991 188881 281337 1068524 551927 306286 210311 33680 33680 144538 138257 6281 808501 236394 417256 154851 30365 12630 7732 10003 22080 2119 17149 2812 130325 17403 56009 56913 112244 19588 58757 33899 27111 6025 15353 5733 76598 22158 54427 13 18487 18487 35178 35178 BAD DEBTS 114621 0 114621 0 DUES AND SUBSCRIPTION 49640 25230 24410 0 EQUIPMENT AND RENTAL 45774 11489 173 34112 EVENT SUPPLIES 37690 37690 0 0 11394 10739 655 10744443 8460867 1487311 796265 2218679 1238683 11444325 8297334 10521177 6172121 136744 338409 52293 33806 14905 360530 24388123 16440883 148094 270843 5878291 1012360 162753 1875372 19778 363764 6208916 3522339 X 8308710 6746423 9870497 6172121 18179207 12918544 24388123 16440883 -5255542 -5121 0 X 0 1 X 1 0 X 1399405 8750114 18221209 7931168 5672165 41974061 1399405 8750114 18221209 7931168 5672165 41974061 9233766 32740295 52 13 48 246733 522299 769145 0 0 0 2221926 0 2221926 44965132 3020838 0.72810 0.98620 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 CURRENT PORTION OF OPERATING LEASE LIABILITIES 363764 363764 X 5529627 -5121 45847 40726 5488901 0 5488901 10790290 45847 45847 10744443 0 10744443 PART X, LINE 2: THE ORGANIZATION FOLLOWS THE PROVISIONS OF UNCERTAIN TAX POSITIONS AS ADDRESSED IN THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) ACCOUNTING STANDARDS CODIFICATION. THE ORGANIZATION RECOGNIZES ACCRUED INTEREST AND PENALTIES ASSOCIATED WITH UNCERTAIN TAX POSITIONS AS PART OF THE INCOME TAX PROVISION, WHEN APPLICABLE. THERE WERE NO AMOUNTS ACCRUED IN THE FINANCIAL STATEMENTS RELATED TO UNCERTAIN TAX POSITIONS FOR THE YEAR ENDED DECEMBER 31, 2024. PADRES PEDAL THE CAUSE 3624612 3413332 211280 175036 10207 16161 715439 3624612 3413332 211280 175036 10207 16161 715439 916843 -705563 1 LA JOLLA INSTITUTE FOR IMMUNOLOGY 9420 ATHENA CIRCLE LA JOLLA CA 92037 330328688 501C3 532374 0 SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. RADY CHILDREN'S HOSPITAL 3020 CHILDRENS WAY MC 5005 SAN DIEGO CA 92123 951691313 501C3 21431 0 SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. SANFORD BURNHAM PREBYS 10901 N TORREY PINES RD LA JOLLA CA 92037 510197108 501C3 411561 0 SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. SCRIPPS RESEARCH 10550 N TORREY PINES RD LA JOLLA CA 92037 951684089 115 188618 0 SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. THE REGENTS OF UNIVERSITY OF CALIFORNIA UC SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 943067788 115 4721574 0 SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 N TORREY PINES RD LA JOLLA CA 92037 952160097 501C3 207926 0 SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. BEKEN BIO INC 1155 ISLAND AVE SUITE 100 SAN DIEGO CA 92101 851922410 250000 0 SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. SEREN BIO CORP 541 GARDENA COURT ENCINITAS CA 92024 933190132 250000 0 SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. PALM THERAPEUTICS INC 3210 MERRYFIELD ROW SAN DIEGO CA 92121 832814106 250000 0 SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. RESOLUTE SCIENCE INC 3210 MERRYFIELD ROW SAN DIEGO CA 92121 852657270 250000 0 SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. 6 4 PART I, LINE 2: THE ORGANIZATION MAINTAINS RECORDS TO SUBSTANTIATE THE AMOUNT OF GRANTS OR ASSISTANCE, AND THE SELECTION CRITERIA USED TO AWARD THE GRANTS OR ASSISTANCE. THE ORGANIZATION'S ABILITY TO FUND GRANTS IS BASED ON CASH RECEIPTS IN A GIVEN CALENDAR YEAR UPON THE RECOMMENDATION OF THE BOARD, THE ORGANIZATION WITHHOLDS OPERATING CAPITAL AND DISBURSES ANY EXCESS CASH TO RESEARCH GRANTS. POTENTIAL GRANTEES ARE REQUIRED TO APPLY FOR RESEARCH FUNDING BY SUBMITTING DOCUMENTATION OF SCIENTIFIC PROCESSES AND METRICS RELATED TO THE POTENTIAL SUCCESS/OUTCOMES OF RESEARCH EFFORTS. THE ORGANIZATION'S SCIENTIFIC ADVISORY BOARD REVIEWS APPLICATIONS AND RECOMMENDS FUNDING BASED ON STRENGTH OF APPLICATION MATERIALS, AND ALIGNMENT OF ORGANIZATIONAL RESEARCH OBJECTIVES. ONCE FUNDED, THE ORGANIZATION REQUIRES GRANTEE TO SUBMIT PROGRESS REPORTS TO RECONCILE USE OF FUNDS AND OUTLINE ACHIEVEMENTS/EFFICACY OF RESEARCH EFFORTS. X X 0 0 0 0 0 0 0 1 0 ANNE MARBARGER CHIEF EXECUTIVE OFFICER 310000 0 75000 0 0 0 13333 0 11780 0 410113 0 0 0 KAREN HOOPER CHIEF OPERATING OFFICER 210000 0 20000 0 0 0 9200 0 13735 0 252935 0 0 0 DANIELLE DAWSON PHILANTHROPY OFFICER 221250 0 0 0 0 0 0 0 9889 0 231139 0 0 0 PART I, LINE 7 ANNE MARBARGER AND KAREN HOOPER RECEIVED PERFORMANCE BONUSES. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE FORM 990 IS PROVIDED TO EACH BOARD MEMBER FOR REVIEW BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY APPLIES TO ALL DIRECTORS AND OFFICERS OF THE ORGANIZATION, AND ANY PERSON WHO IS IN A POSITION OT EXERCISE SUBSTANTIAL INFLUENCE OVER THE DECISIONS AND AFFAIRS FO THE ORGANIZATION. ALL DIRECTORS AND OFFICERS OF THE ORGANIZATION ARE REQUIRED TO FILE AN ANNUAL DISCLOSURE STATEMENT WIT THE BOARD OF DIRECTORS. IF AN INTERESTED PERSON HAS A POSITION OF FINANCIAL INTEREST IN ANY BUSINESS OR OTHER ENTITY WITH THE CORPORATION IS CONSIDERING ENTERING INTO AN ARRANGEMENT OR TRANSACTION, THE INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER PORTION OF FINANCIAL INTEREST AND ALL MATERIAL FACTS FO THE ORGANIZATIONS BOARD OF DIRECTORS AS SOON AS THE INTERESTED PERSON HAS KNOWLEDGE OF THE POTENTIAL ARRANGEMENT OR TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF OFFICERS AND KEY EMPLOYEES ARE APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION C, LINE 19 ANY DOCUMENTS AS STIPULATED BY LAW ARE AVAILABLE TO THE PUBLIC UPON REQUEST.